Venom from the deadliest spider in Australia could hold the key to a future treatment for stroke, scientists have said.
A protein found in the toxic venom of the funnel web spider was found to help prevent brain damage after stroke in lab rats.
Researchers from the University of Queensland and Monash University captured three funnel web spiders, whose bite can kill humans in 15 minutes, for a study.
They used pipettes to ‘milk’ the spiders for their venom which they analysed, spotting a protein called Hi1a as it resembled two copies of another chemical that can protect brain cells.
The scientists recreated the protein and injected it into rats. They found it blocked ion channels in the brain which are sensitive to acid and play an important role in brain damage after strokes.
In the study, published in the journal Proceedings of the National Academy of Sciences, they described Hi1a as “highly neuroprotective” in models of what happens when someone suffers a stroke.
A stroke is a serious and potentially deadly brain attack, which happens when the blood supply to part of the brain is cut off, or when a blood vessel supplying the brain bursts.
Someone in the world has a stroke every two seconds and they occurred 152,000 times in the UK in 2016, according to the Stroke Association.
“This world-first discovery will help us provide better outcomes for stroke survivors by limiting the brain damage and disability caused by this devastating injury,” said Glenn King, who led the research.
“Hi1a even provides some protection to the core brain region most affected by oxygen deprivation, which is generally considered unrecoverable due to the rapid cell death caused by stroke.“
Health news in pictures
Kate Holmes, deputy director for research at the Stroke Association, said she welcomed the research but it is still unknown whether the protein could be used in future treatments for humans.
“We welcome any treatment that has the potential to reduce the damage caused by stroke, particularly if this can benefit people who are unable to arrive at hospital quickly,” she said.
“Current treatments must be given in half this time period, and it is too early for us to know if this research can offer an alternative for stroke patients.”
<!– Reuse content–>